Australian infectious disease therapy and vaccine development company BioDiem Ltd (BDM) announced that it has signed an agreement to license a novel vaccine technology from the University of Canberra, expanding the potential disease targets of BioDiem’s technology portfolio. Research to date supports the technology’s use in the development of vaccines for hepatitis including hepatitis B and D, which currently have no curative treatment. The new agreement provides BioDiem with an exclusive license to a novel vaccine technology which, although in development for hepatitis, may also have applicability in a range of other diseases. All terms are in keeping with industry standards, and as part of the agreement BioDiem has established a collaborative research program with the University of Canberra to develop the technology further.
“We’re very pleased to establish an important research partnership with the University of Canberra and its world- leading researchers. This technology is built on excellent science and the potential applications in hepatitis are very exciting. As with our other recent acquisitions we have the in-house expertise to significantly boost the value of this asset, and believe that development towards a high-value orphan indication may allow us to achieve a rapid entry to clinical trials and eventual outlicensing,” said BioDiem CEO Julie Phillips.
BioDiem is an ASX-listed company based in Melbourne with an international focus on discovering, developing and commercialising world-class research and technology targeting cancers and infectious diseases. BioDiem’s core technologies include the Live Attenuated Influenza Virus (LAIV), the Savine platform and the BDM-I antimicrobial compound. The University of Canberra has a dynamic, innovative and collaborative research culture with a focus on applied research in areas aligned with the needs of our local community as well as national and international research priorities. External collaboration and engagement with academic, government, industry and community partners are highly valued and supported throughout the University’s research work.
Tags: BDM, BioDeim, Biotechnology, License agreement, University of Canberra
